Bioluminescence monitoring of intracranial glioblastoma xenograft: Response to primary and salvage temozolomide therapy

Keyphrases

• Temozolomide 100%
• Glioblastoma Xenografts 100%
• Bioluminescent Assay 100%
• Bioluminescence Imaging 80%
• Survival Benefit 30%
• Imaging Monitoring 20%
• Treatment Group 20%
• Antitumor Effect 20%
• Intracranial Tumor 20%
• Tumor Regrowth 20%
• Response to Therapy 10%
• Xenograft 10%
• Cell Response 10%
• Mouse Model 10%
• Clinically Significant 10%
• Rodent Models 10%
• Glioblastoma multiforme 10%
• Tumor Cell Proliferation 10%
• Luciferase 10%
• Imaging Applications 10%
• Therapeutic Regimen 10%
• Retreatment 10%
• Therapy Efficacy 10%
• Initial Treatment 10%
• Lentivirus 10%
• Small Animal Imaging 10%
• Survival Prediction 10%
• Single High Dose 10%
• Salvage Therapy 10%
• Athymic nude Mice 10%
• Relative Survival 10%
• Methylating Agent 10%
• Recurrent Glioblastoma multiforme 10%
• Supratentorial Tumor 10%
• Survival Comparison 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Glioblastoma 100%
• Temozolomide 100%
• Intracranial Tumor 30%
• Neoplasm 20%
• Minoxidil 20%
• Treatment Group 20%
• Mouse Model 10%
• Nude Mouse 10%
• Tumor Growth 10%
• Lentivirus 10%
• Luciferase 10%

Neuroscience

• Temozolomide 100%
• Bioluminescence 100%
• Intracranial Tumor 30%
• Glioblastoma Multiforme 20%
• Minoxidil 20%
• Luciferase 10%
• Longitudinal Study 10%
• Cell Growth 10%